Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference21 articles.
1. Malenka RC, Nestler EJ, Hyman SE, Sydor A, Brown RY (eds.). Molecular neuropharmacology: a foundation for clinical neuroscience, 2nd ed. New York: McGraw-Hill Medical, pp. 190–191, 287; 2009.
2. US Food and Drug Administration. Kaleo briefing on naloxone HCl. Joint Meeting of the Anesthetic and Analgesic Drug Products and the Drug Safety and Risk Management Advisory Committees October 5, 2016 kaleo, Inc. Briefing Dossier.
3. Dowling J, Isbister GK, Kirkpatrick CMJ, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30:490–6. https://doi.org/10.1097/FTD.0b013e3181816214.
4. Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56:1243–53. https://doi.org/10.1002/jcph.759.
5. McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, Smith K, Strang J. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction. 2017;113:484–93. https://doi.org/10.1111/add.14033.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献